Astellas Pharma Goes Hostile on OSI
Here we go again, another hostile take over attempt. Today, Astellas Pharma made a hostile bid for OSI Pharmaceuticals (Ticker: OSIP) for $52.00 per share in cash. Astellas Pharma is not going to let this one get away like CV Therapeutics. Astellas Pharma lost the bidding war for CV Therapeutics to Gilead Sciences (Ticker: GILD) in early 2009. I see a very high probability that Astellas Pharma will end up with OSI Pharmaceuticals at a much higher price. I picked up some OSI Pharmaceuticals at $55.93. The fun is just beginning…
posted by Money Turtle @ 12:30 PM
2 comments
2 Comments:
Hi found your site browsing through perfinance blogs.
You appear to advocating the purchase of individual stocks -- how do you reconcile this with your training as a scientist (biology) / and finance. The overwhelming evidence for the EMH suggests that picking individual stocks is a losers game.
Yes, I do believe the market is a very efficient discounting machine, but it’s not perfect. Over the long haul, the academics have shown that all you have to do a buy and hold an index fund and you’ll beat the majority of the money managers. I have a Total Market Index in my IRA. But in the short term, I’ve observed lots of inefficiencies in the markets and if you do some digging, you can take advantage of the inefficiencies and beat the market on a risk adjusted basis. Right now, my focus is on M&A because it’s presenting some decent returns with relatively low risk. I’ve learned that you have to be flexible and adapt to changes in the market if you want to try to beat the market. Trading is not for everyone. But like I said, in the long term an index fund is the way to go…
Post a Comment
<< Home